Renato

Renato Therapeutics was a pre-clinical stage biotechnology company focused on developing next-generation chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of solid tumors. The company's technology originated from research at the University of Pennsylvania, a leading institution in the field of cellular immunotherapy. In December 2020, Renato Therapeutics was acquired by Janssen Biotech, a subsidiary of Johnson & Johnson, to bolster Janssen's portfolio in the oncology and cell therapy space. The acquisition aimed to leverage Renato's innovative CAR-T platform to address unmet needs in difficult-to-treat cancers that have historically been resistant to traditional cell therapies.